"ritlecitinib" meaning in All languages combined

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "ritlecitinib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with 1 entry",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "other",
          "name": "Pages with entries",
          "parents": [],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Pharmaceutical drugs",
          "orig": "en:Pharmaceutical drugs",
          "parents": [
            "Drugs",
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Healthcare",
            "Fundamental",
            "Health",
            "Body"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2173:",
          "text": "Ritlecitinib is an irreversible covalent inhibitor that binds to a distinct cysteine residue in the JAK3 catalytic domain, which other JAK family members lack. […] Ritlecitinib was found to be superior to placebo in a phase II study in RA patients with an inadequate response to MTX (76).",
          "type": "quote"
        }
      ],
      "glosses": [
        "A medication belonging to the class of Tec/Janus kinase inhibitors, used for the treatment of alopecia areata."
      ],
      "id": "en-ritlecitinib-en-noun-IF-xz2K7",
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "medication",
          "medication"
        ],
        [
          "Tec",
          "Tec"
        ],
        [
          "Janus kinase",
          "Janus kinase"
        ],
        [
          "inhibitor",
          "inhibitor"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "alopecia areata",
          "alopecia areata"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A medication belonging to the class of Tec/Janus kinase inhibitors, used for the treatment of alopecia areata."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "ritlecitinib"
}

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "ritlecitinib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms with quotations",
        "English uncountable nouns",
        "Pages with 1 entry",
        "Pages with entries",
        "en:Pharmaceutical drugs"
      ],
      "examples": [
        {
          "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2173:",
          "text": "Ritlecitinib is an irreversible covalent inhibitor that binds to a distinct cysteine residue in the JAK3 catalytic domain, which other JAK family members lack. […] Ritlecitinib was found to be superior to placebo in a phase II study in RA patients with an inadequate response to MTX (76).",
          "type": "quote"
        }
      ],
      "glosses": [
        "A medication belonging to the class of Tec/Janus kinase inhibitors, used for the treatment of alopecia areata."
      ],
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "medication",
          "medication"
        ],
        [
          "Tec",
          "Tec"
        ],
        [
          "Janus kinase",
          "Janus kinase"
        ],
        [
          "inhibitor",
          "inhibitor"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "alopecia areata",
          "alopecia areata"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A medication belonging to the class of Tec/Janus kinase inhibitors, used for the treatment of alopecia areata."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "ritlecitinib"
}